Telomerase in cancer: Clinical applications

Virginia Urquidi, David Tarin, Steven Goodison

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

The biology of telomeres and telomerase has been the subject of intensive investigative effort since it became evident that they play a significant role in two important biological processes, the loss of cellular replicative capacity inherent to organismal ageing and the unrestricted cell proliferation characteristic of carcinogenesis. Telomere shortening in normal cells is a result of DNA replication events, and reduction beyond a critical length is a signal for cellular senescence. One of the cellular mechanisms used to overcome proliferative restriction is the activation of the enzyme telomerase, which replaces the loss of telomeric DNA that occurs at each cell division. Studies have demonstrated that tumours have shorter telomeres than normal tissue and that telomerase is activated in up to 90% of all human cancers while it is present only in a limited range of normal adult tissues. The role of telomerase in the extension of the cellular replicative lifespan has recently been shown by ectopic expression of the enzyme, being consistent with the oncogenesis model whereby the acquisition of an 'immortal' phenotype is a requirement for advanced tumour progression. In this article we review the present knowledge of telomeres and telomerase in cancer and discuss the potential use of this enzyme as a diagnostic and prognostic tumour marker and as a target for cancer therapy.

Original languageEnglish (US)
Pages (from-to)419-430
Number of pages12
JournalAnnals of Medicine
Volume30
Issue number5
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Telomerase
Telomere
Neoplasms
Carcinogenesis
Telomere Shortening
Biological Phenomena
Enzyme Activation
Cell Aging
Enzymes
Tumor Biomarkers
DNA Replication
Cell Division
Reference Values
Cell Proliferation
Phenotype
DNA

Keywords

  • Cancer
  • Human telomerase reverse transcriptase (hTERT)
  • Replicative senescence
  • Telomerase
  • Telomere shortening
  • Tumour

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Telomerase in cancer : Clinical applications. / Urquidi, Virginia; Tarin, David; Goodison, Steven.

In: Annals of Medicine, Vol. 30, No. 5, 01.01.1998, p. 419-430.

Research output: Contribution to journalReview article

Urquidi, Virginia ; Tarin, David ; Goodison, Steven. / Telomerase in cancer : Clinical applications. In: Annals of Medicine. 1998 ; Vol. 30, No. 5. pp. 419-430.
@article{cb2c72b90deb41f2b2aa2bbb644fc8d8,
title = "Telomerase in cancer: Clinical applications",
abstract = "The biology of telomeres and telomerase has been the subject of intensive investigative effort since it became evident that they play a significant role in two important biological processes, the loss of cellular replicative capacity inherent to organismal ageing and the unrestricted cell proliferation characteristic of carcinogenesis. Telomere shortening in normal cells is a result of DNA replication events, and reduction beyond a critical length is a signal for cellular senescence. One of the cellular mechanisms used to overcome proliferative restriction is the activation of the enzyme telomerase, which replaces the loss of telomeric DNA that occurs at each cell division. Studies have demonstrated that tumours have shorter telomeres than normal tissue and that telomerase is activated in up to 90{\%} of all human cancers while it is present only in a limited range of normal adult tissues. The role of telomerase in the extension of the cellular replicative lifespan has recently been shown by ectopic expression of the enzyme, being consistent with the oncogenesis model whereby the acquisition of an 'immortal' phenotype is a requirement for advanced tumour progression. In this article we review the present knowledge of telomeres and telomerase in cancer and discuss the potential use of this enzyme as a diagnostic and prognostic tumour marker and as a target for cancer therapy.",
keywords = "Cancer, Human telomerase reverse transcriptase (hTERT), Replicative senescence, Telomerase, Telomere shortening, Tumour",
author = "Virginia Urquidi and David Tarin and Steven Goodison",
year = "1998",
month = "1",
day = "1",
doi = "10.3109/07853899809002483",
language = "English (US)",
volume = "30",
pages = "419--430",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Telomerase in cancer

T2 - Clinical applications

AU - Urquidi, Virginia

AU - Tarin, David

AU - Goodison, Steven

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The biology of telomeres and telomerase has been the subject of intensive investigative effort since it became evident that they play a significant role in two important biological processes, the loss of cellular replicative capacity inherent to organismal ageing and the unrestricted cell proliferation characteristic of carcinogenesis. Telomere shortening in normal cells is a result of DNA replication events, and reduction beyond a critical length is a signal for cellular senescence. One of the cellular mechanisms used to overcome proliferative restriction is the activation of the enzyme telomerase, which replaces the loss of telomeric DNA that occurs at each cell division. Studies have demonstrated that tumours have shorter telomeres than normal tissue and that telomerase is activated in up to 90% of all human cancers while it is present only in a limited range of normal adult tissues. The role of telomerase in the extension of the cellular replicative lifespan has recently been shown by ectopic expression of the enzyme, being consistent with the oncogenesis model whereby the acquisition of an 'immortal' phenotype is a requirement for advanced tumour progression. In this article we review the present knowledge of telomeres and telomerase in cancer and discuss the potential use of this enzyme as a diagnostic and prognostic tumour marker and as a target for cancer therapy.

AB - The biology of telomeres and telomerase has been the subject of intensive investigative effort since it became evident that they play a significant role in two important biological processes, the loss of cellular replicative capacity inherent to organismal ageing and the unrestricted cell proliferation characteristic of carcinogenesis. Telomere shortening in normal cells is a result of DNA replication events, and reduction beyond a critical length is a signal for cellular senescence. One of the cellular mechanisms used to overcome proliferative restriction is the activation of the enzyme telomerase, which replaces the loss of telomeric DNA that occurs at each cell division. Studies have demonstrated that tumours have shorter telomeres than normal tissue and that telomerase is activated in up to 90% of all human cancers while it is present only in a limited range of normal adult tissues. The role of telomerase in the extension of the cellular replicative lifespan has recently been shown by ectopic expression of the enzyme, being consistent with the oncogenesis model whereby the acquisition of an 'immortal' phenotype is a requirement for advanced tumour progression. In this article we review the present knowledge of telomeres and telomerase in cancer and discuss the potential use of this enzyme as a diagnostic and prognostic tumour marker and as a target for cancer therapy.

KW - Cancer

KW - Human telomerase reverse transcriptase (hTERT)

KW - Replicative senescence

KW - Telomerase

KW - Telomere shortening

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=0031757138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031757138&partnerID=8YFLogxK

U2 - 10.3109/07853899809002483

DO - 10.3109/07853899809002483

M3 - Review article

C2 - 9814828

AN - SCOPUS:0031757138

VL - 30

SP - 419

EP - 430

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 5

ER -